Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (:Drugs) EQUITY
$54.08
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | TEVA Avg Daily Volume: 6,165,400
Last Update: 02/11/16 - 4:00 PM EST
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $54.08
52 Week Range: $53.78 - $72.31
Oustanding Shares: 852,000,000
Market Cap: 48,487,320,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 12 10
Moderate Buy 2 2 2 2
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1
Mean Rec. 1.56 1.56 1.53 1.79
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
0.00 27.60 27.18
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue -0.20 0.11 0.03
Net Income 142.80 0.10 0.03
EPS 138.50 0.15 0.05
Earnings for TEVA:
EBITDA 6.00B
Revenue 20.27B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $1.48 $1.45 $5.67 $5.85
Number of Analysts 1 1 6 6
High Estimate $1.48 $1.45 $6.03 $6.51
Low Estimate $1.48 $1.45 $5.30 $5.21
Prior Year $1.36 $1.43 $5.42 $5.67
Growth Rate (Year over Year) 8.82% 1.40% 4.67% 3.11%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jan 7, 2016 | 12:00 PM EST

Mylan and Endo International look like bargains at current prices.

By

David Katz

 | Dec 4, 2015 | 7:00 AM EST

History indicates pharmaceutical companies with low multiples offer payoffs down the road.

By

David Katz

 | Dec 2, 2015 | 7:11 AM EST

Look for 2015's record run of mergers and acquisitions to continue.

By

Timothy Collins

 | Nov 25, 2015 | 2:00 PM EST

They are a diverse group that could work well as a basket.

By

Jim Cramer and Jack Mohr

 | Nov 23, 2015 | 9:00 AM EST

The combined company will provide lots of opportunities.

By

Bret Jensen

 | Nov 17, 2015 | 9:00 AM EST

These two will continue to churn out earnings growth.

By

Jim Cramer and Jack Mohr

 | Nov 13, 2015 | 8:00 AM EST

We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.

By

Bret Jensen

 | Nov 4, 2015 | 10:15 AM EST
Markets were slightly up on the open, but I wouldn't be surprised to see some profit-taking today after Wall Street started November with two big days of gains.
By

David Katz

 | Nov 4, 2015 | 7:00 AM EST

AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.

By

Jim Cramer and Jack Mohr

 | Oct 29, 2015 | 10:48 AM EDT

Reports of merger talks have been confirmed, and we believe the two pharma giants would both benefit from the deal.

In today's opener, Jimmy suggests that one shouldnt buy JPMorgan's shares simply because C...

Should read... The U.S. dollar continued to experience WEAKNESS

Reasons to trail down stops on shorts in the indices and also to consider longs if the buy...

JPMorgan Chase's CEO Jamie Dimon buys 500K shares of the company - CNBC, citing DJ

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.